MORRISVILLE, N.C., June 28, 2012 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) today announced that it plans to report fiscal-year 2012 financial results on Form 10-K on Tuesday, July 24, 2012. Furthermore, on Wednesday, July 25, 2012, at 11 a.m. EDT, Company President and Chief Financial Officer Michael Jebsen will host a conference call and live webcast to discuss the 2012 financial results and the company's progress.
To access the live teleconference, dial (866) 770-7125 (U.S. and Canada), or (617) 213-8066 (international). The participant pass code is 98948399. Also, a link to access a live webcast of the teleconference will be available in the Investor section of the company's website. A replay of the webcast will be available by phone or on the Oxygen website for a limited time. To access the replay by phone, call (888) 286-8010 (U.S. and Canada) or (617) 801-6888 (international). The pass code for the replay is 42947311.
The Company also announced it will host its General Annual Meeting on Friday, August 31, 2012, at 9 a.m. EDT, at Wells Fargo Capitol Center, 150 Fayetteville Street, 23rd Floor, Room, 2368, Raleigh, NC 27601. The annual meeting is open to shareholders of record as of July 23, 2012. This event will be broadcast via a conference call and webcast. To access the live meeting via telephone, dial 800-901-5241 (U.S. & Canada) or 617-786-2963 (international) and enter the pass code 58960968. To access the live webcast, go to the Investor section of the company's website and click on the available link. A question and answer session is available only in person or via the teleconference, and is not accessible via the webcast. Shareholders who attend the meeting in person should be prepared to provide photo identification for admission.
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte® that is currently in clinical and preclinical studies for intravenous delivery for indications such as traumatic brain injury, decompression sickness and stroke. The company is also developing PFC-based creams and gels for topical delivery to the skin for dermatologic conditions and potentially wound care. In addition, the company has commercialized its Dermacyte® line of skin care cosmetics for the anti-aging market.
The Oxygen Biotherapeutics, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7277
Caution Regarding Forward-Looking Statements
This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the company's judgment as of the date of this release. The forward-looking statements are subject to a number of risks and uncertainties including matters beyond the company's control that could lead to delays and other risks and uncertainties as described in our filings with the Securities and Exchange Commission, including in the current reports on Form 10-Q and Form-10K. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.